Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher After Analyst Upgrade

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price traded up 7.3% during mid-day trading on Thursday after Cantor Fitzgerald raised their price target on the stock from $25.00 to $30.00. Cantor Fitzgerald currently has an overweight rating on the stock. Capricor Therapeutics traded as high as $18.25 and last traded at $18.15. 216,121 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,141,077 shares. The stock had previously closed at $16.91.

CAPR has been the subject of a number of other reports. Maxim Group lifted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the company’s stock in a transaction on Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 65.21 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently modified their holdings of CAPR. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the period. PFM Health Sciences LP purchased a new position in shares of Capricor Therapeutics in the third quarter worth $2,324,000. Marshall Wace LLP purchased a new position in shares of Capricor Therapeutics in the second quarter worth $426,000. Renaissance Technologies LLC lifted its holdings in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the second quarter worth $147,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Stock Up 9.3 %

The firm’s fifty day moving average price is $14.63 and its 200 day moving average price is $8.29. The stock has a market cap of $839.63 million, a PE ratio of -19.88 and a beta of 4.00.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.